東方生物(688298.SH):新冠抗原自測試劑獲得英國EUA特殊使用授權
格隆匯6月9日丨東方生物(688298.SH)公佈,公司新型冠狀病毒抗原自測試劑於近期取得英國EUA特殊使用授權證書。產品名稱為Rapid COVID-19 (Antigen) Self-test新型冠狀病毒抗原自測試劑,有效期截至2021年8月28日。
該試劑採用鼻拭子樣本檢測是否感染COVID-19,用於有症狀和無症狀的個體檢測。
公司表示,該次新型冠狀病毒抗原自測試劑獲得英國EUA特殊使用授權,符合英國當地授權認證要求和新冠疫情不斷變化的檢測需求,有利於公司進一步拓寬新冠抗原檢測試劑在英國的應用場景。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.